Literature DB >> 19053299

Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels.

Raghavendra S Navath1, Yunus E Kurtoglu, Bing Wang, Sujatha Kannan, Robert Romero, Rangaramanujam M Kannan.   

Abstract

N-Acetyl-L-cysteine (NAC) is an antioxidant and anti-inflammatory agent with significant potential in clinical applications including stroke and neuroinflammation. The drug shows high plasma binding upon IV administration, requiring high doses and associated side effects. Through the use of an appropriate delivery vehicle, the stability and efficacy of NAC can be significantly improved. Dendrimers are an emerging class of nanoscale drug delivery vehicles, which enable high drug payloads and intracellular delivery. Poly(amidoamine) (PAMAM) dendrimer-NAC conjugates having cleavable disulfide linkages are designed for intracellular delivery based on glutathione levels. We have successfully synthesized two conjugates with a cationic G4-NH(2) and an anionic G3.5-COOH PAMAM dendrimer with NAC payloads of 16 and 18 per dendrimer, respectively, as confirmed by (1)H NMR and MALDI-TOF analysis. NAC release from the conjugates at intracellular and extracellular glutathione (GSH) concentrations were evaluated by reverse phase HPLC (RP-HPLC) analysis, and approximately 70% of NAC payload was released within one hour at intracellular GSH concentrations (approximately 10 mM), whereas negligible NAC release was observed at extracellular GSH levels (2 microM). FITC-labeled conjugates showed that they enter cells rapidly and localize in the cytoplasm of lipopolysaccharide (LPS)-activated microglial cells (the target cells in vivo). The significantly improved efficacies of dendrimer-NAC conjugates in activated microglial cells was confirmed by measuring the nitrite inhibition in the cell culture medium, which is an indication of the antioxidative property of the drug. Both G4-NH(2) and G3.5-COOH conjugates showed significantly better nitrite inhibition both at 24 and 72 h compared to free NAC, by as much as a factor of 16. The results indicate that PAMAM dendrimer conjugates produce higher local NAC concentration inside the cells, with GSH-sensitive disulfide linker enabling efficient and rapid cellular release of the drug.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053299      PMCID: PMC2727757          DOI: 10.1021/bc800342d

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  44 in total

1.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.

Authors:  M Tepel; M van der Giet; C Schwarzfeld; U Laufer; D Liermann; W Zidek
Journal:  N Engl J Med       Date:  2000-07-20       Impact factor: 91.245

2.  Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine.

Authors:  R N Dilger; D H Baker
Journal:  J Anim Sci       Date:  2007-03-19       Impact factor: 3.159

3.  A study of glutathione status in the blood and tissues of patients with breast cancer.

Authors:  Chih-Ching Yeh; Ming-Feng Hou; Szu-Hsien Wu; Shih-Meng Tsai; Shu-Kai Lin; Linda Ann Hou; Hsu Ma; Li-Yu Tsai
Journal:  Cell Biochem Funct       Date:  2006 Nov-Dec       Impact factor: 3.685

4.  N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps.

Authors:  R D Estensen; M Levy; S J Klopp; A R Galbraith; J S Mandel; J A Blomquist; L W Wattenberg
Journal:  Cancer Lett       Date:  1999-12-01       Impact factor: 8.679

5.  N-acetylcysteine in acute hepatic failure (non-paracetamol-induced).

Authors:  Z Ben-Ari; H Vaknin; R Tur-Kaspa
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

6.  N-acetyl-cysteine suppresses amniotic fluid and placenta inflammatory cytokine responses to lipopolysaccharide in rats.

Authors:  Ron Beloosesky; Dave A Gayle; Fataneh Amidi; Sonia E Nunez; Jooby Babu; Mina Desai; Michael G Ross
Journal:  Am J Obstet Gynecol       Date:  2006-01       Impact factor: 8.661

7.  Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials.

Authors:  R Breitkreutz; N Pittack; C T Nebe; D Schuster; J Brust; M Beichert; V Hack; V Daniel; L Edler; W Dröge
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

8.  Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.

Authors:  L M Hinman; P R Hamann; R Wallace; A T Menendez; F E Durr; J Upeslacis
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

9.  Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis.

Authors:  E S Louwerse; G J Weverling; P M Bossuyt; F E Meyjes; J M de Jong
Journal:  Arch Neurol       Date:  1995-06

10.  N-acetylcysteine (D- and L-stereoisomers) prevents apoptotic death of neuronal cells.

Authors:  G Ferrari; C Y Yan; L A Greene
Journal:  J Neurosci       Date:  1995-04       Impact factor: 6.167

View more
  33 in total

1.  Multifunctional Dendrimer-templated Antibody Presentation on Biosensor Surfaces for Improved Biomarker Detection.

Authors:  Hye Jung Han; Rangaramanujam M Kannan; Sunxi Wang; Guangzhao Mao; Juan Pedro Kusanovic; Roberto Romero
Journal:  Adv Funct Mater       Date:  2010-02-08       Impact factor: 18.808

2.  Effect of mannose targeting of hydroxyl PAMAM dendrimers on cellular and organ biodistribution in a neonatal brain injury model.

Authors:  Anjali Sharma; Joshua E Porterfield; Elizabeth Smith; Rishi Sharma; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  J Control Release       Date:  2018-06-05       Impact factor: 9.776

3.  Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates.

Authors:  Anupa R Menjoge; Raghavendra S Navath; Abbas Asad; Sujatha Kannan; Chong J Kim; Roberto Romero; Rangaramanujam M Kannan
Journal:  Biomaterials       Date:  2010-03-25       Impact factor: 12.479

Review 4.  Experimental and theoretical investigations in stimuli responsive dendrimer-based assemblies.

Authors:  Mijanur Rahaman Molla; Poornima Rangadurai; Giovanni M Pavan; S Thayumanavan
Journal:  Nanoscale       Date:  2015-03-07       Impact factor: 7.790

5.  Redox Potential-Sensitive N-Acetyl Cysteine-Prodrug Nanoparticles Inhibit the Activation of Microglia and Improve Neuronal Survival.

Authors:  Eleni Markoutsa; Peisheng Xu
Journal:  Mol Pharm       Date:  2017-04-04       Impact factor: 4.939

6.  Systemic dendrimer-drug treatment of ischemia-induced neonatal white matter injury.

Authors:  Elizabeth Nance; Michael Porambo; Fan Zhang; Manoj K Mishra; Markus Buelow; Rachel Getzenberg; Michael Johnston; Rangaramanujam M Kannan; Ali Fatemi; Sujatha Kannan
Journal:  J Control Release       Date:  2015-07-13       Impact factor: 9.776

7.  A dendrimer-based immunosensor for improved capture and detection of tumor necrosis factor-α cytokine.

Authors:  Admira Bosnjakovic; Manoj K Mishra; Hye Jung Han; Roberto Romero; Rangaramanujam M Kannan
Journal:  Anal Chim Acta       Date:  2012-01-18       Impact factor: 6.558

Review 8.  Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.

Authors:  Su-Tang Lo; Amit Kumar; Jer-Tsong Hsieh; Xiankai Sun
Journal:  Mol Pharm       Date:  2013-01-24       Impact factor: 4.939

9.  Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery.

Authors:  Yunus E Kurtoglu; Raghavendra S Navath; Bing Wang; Sujatha Kannan; Robert Romero; Rangaramanujam M Kannan
Journal:  Biomaterials       Date:  2009-01-25       Impact factor: 12.479

10.  Click hybridization of immune cells and polyamidoamine dendrimers.

Authors:  Leyuan Xu; Olga Yu Zolotarskaya; W Andrew Yeudall; Hu Yang
Journal:  Adv Healthc Mater       Date:  2014-02-13       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.